Elevation Oncology, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Elevation Oncology discontinues EO-3021 development, focuses on EO-1022, and initiates a strategic review to maximize shareholder value in its Q1 2025 report.
Elevation Oncology's Q3 2024 report highlights progress in the EO-3021 clinical trial and financial updates, including a net loss of $12.9 million.
Elevation Oncology's Q2 2024 report highlights progress in its EO-3021 clinical trial and financial updates, including a net loss of $10.5 million.
Elevation Oncology's first quarter 2024 results show a net loss of $10.7 million, but the company's cash position has improved to $104.1 million.